The safety of concurrent use of Deferiprone and Vitamin C has not been formally studied. Based on the reported adverse interaction that can occur between deferoxamine and Vitamin C, caution should be used when administering concurrent Deferiprone and Vitamin C. It should not be given with aluminium containing antacids.
Gastrointestinal disorders such as diarrhoea, nausea, vomiting and abdominal pain are common during deferiprone treatment and may require temporary reduction in dose. A reddish brown discoloration of the urine is also common. Other adverse effects that have been reported include arthralgia and increased liver enzymes.
Deferiprone is not recommended for use in pregnant & lactating women.
Deferiprone has been shown to cause neutropenia including agranulocytosis. The patients neutrophil count should be monitored every week. Caution is advised in patients with hepatic or renal impairment.
Antidote preparations
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
